Arcutis Biotherapeutics (ARQT) Competitors $13.42 +0.43 (+3.31%) Closing price 04:00 PM EasternExtended Trading$13.48 +0.06 (+0.42%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARQT vs. BPMC, TLX, ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, TGTX, and KRYSShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), TG Therapeutics (TGTX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Arcutis Biotherapeutics vs. Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Verona Pharma Grifols TG Therapeutics Krystal Biotech Arcutis Biotherapeutics (NASDAQ:ARQT) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Does the media prefer ARQT or BPMC? In the previous week, Blueprint Medicines had 26 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 31 mentions for Blueprint Medicines and 5 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.29 beat Blueprint Medicines' score of 0.24 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Blueprint Medicines 6 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ARQT or BPMC? Arcutis Biotherapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Does the MarketBeat Community favor ARQT or BPMC? Blueprint Medicines received 482 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 68.30% of users gave Blueprint Medicines an outperform vote while only 65.63% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformArcutis BiotherapeuticsOutperform Votes6365.63% Underperform Votes3334.38% Blueprint MedicinesOutperform Votes54568.30% Underperform Votes25331.70% Is ARQT or BPMC more profitable? Blueprint Medicines has a net margin of -13.19% compared to Arcutis Biotherapeutics' net margin of -140.97%. Blueprint Medicines' return on equity of -77.49% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-140.97% -119.11% -45.95% Blueprint Medicines -13.19%-77.49%-20.84% Which has better earnings & valuation, ARQT or BPMC? Blueprint Medicines has higher revenue and earnings than Arcutis Biotherapeutics. Blueprint Medicines is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$59.61M26.53-$262.14M-$1.79-7.55Blueprint Medicines$508.82M12.09-$67.09M-$1.08-89.10 Do analysts recommend ARQT or BPMC? Arcutis Biotherapeutics presently has a consensus target price of $16.60, suggesting a potential upside of 22.86%. Blueprint Medicines has a consensus target price of $123.83, suggesting a potential upside of 28.68%. Given Blueprint Medicines' higher probable upside, analysts clearly believe Blueprint Medicines is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 SummaryBlueprint Medicines beats Arcutis Biotherapeutics on 12 of the 17 factors compared between the two stocks. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58B$6.96B$5.81B$9.11BDividend YieldN/A2.88%5.28%3.98%P/E Ratio-7.565.8125.1319.10Price / Sales26.53324.24470.3178.98Price / CashN/A75.0445.1138.24Price / Book14.376.487.635.10Net Income-$262.14M$138.54M$3.19B$246.05M7 Day Performance9.76%-0.69%-0.17%-0.55%1 Month Performance6.55%0.86%3.10%0.33%1 Year Performance42.52%-2.11%19.23%15.29% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics1.5569 of 5 stars$13.42+3.3%$16.60+23.7%+39.4%$1.57B$59.61M-7.50150Upcoming EarningsBPMCBlueprint Medicines3.0652 of 5 stars$93.94-1.3%$123.83+31.8%+4.2%$5.97B$249.38M-44.52640Earnings ReportAnalyst RevisionTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/APositive NewsGap UpELANElanco Animal Health4.1177 of 5 stars$11.26-3.4%$16.29+44.7%-30.9%$5.57B$4.42B28.159,300LNTHLantheus4.5471 of 5 stars$79.94-2.5%$131.86+64.9%+41.6%$5.56B$1.30B13.30700Analyst RevisionNUVLNuvalent1.8935 of 5 stars$77.93-3.7%$112.36+44.2%-6.9%$5.54BN/A-22.4640Upcoming EarningsCYTKCytokinetics4.2226 of 5 stars$46.16+10.9%$82.00+77.6%-39.7%$5.45B$7.53M-8.58250News CoverageHigh Trading VolumeVRNAVerona Pharma2.0277 of 5 stars$64.21+4.1%$57.14-11.0%+272.0%$5.13B$460,000.00-33.4430GRFSGrifols2.2357 of 5 stars$7.32-2.0%N/A-12.9%$5.03B$7.13B6.2023,737Upcoming EarningsTGTXTG Therapeutics4.4546 of 5 stars$30.71-0.1%$40.67+32.4%+124.2%$4.78B$233.66M-307.07290News CoveragePositive NewsKRYSKrystal Biotech4.5264 of 5 stars$153.24-1.6%$206.67+34.9%+55.1%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastShort Interest ↓News CoverageGap Up Related Companies and Tools Related Companies BPMC Competitors TLX Competitors ELAN Competitors LNTH Competitors NUVL Competitors CYTK Competitors VRNA Competitors GRFS Competitors TGTX Competitors KRYS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARQT) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
